Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Alphamedix

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alphamedixtm Phase 2 Data Back New Targeted Alpha Therapy
    Alphamedixtm Phase 2 Data Back New Targeted Alpha Therapy

    21 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-21/esmo-alphamedixtm-phase-2-data-support-first-in-class-potential-of-new-targeted-alpha-therapy-in-gastroenteropancreatic-neuroendocrine-tumors

    PHARMIWEB
    21 Oct 2025
    Share Share
    Alphamedixtm Phase 2 Data Back New Targeted Alpha Therapy
    Alphamedixtm Phase 2 Data Back New Targeted Alpha Therapy

    20 Oct 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-10-20-06-30-00-3169092

    PRESS RELEASE
    20 Oct 2025
    Share Share
    Sanofi $110 M Radioligand Therapy Hits Main Goal in Ph. 2 Trial
    Sanofi $110 M Radioligand Therapy Hits Main Goal in Ph. 2 Trial

    09 Oct 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-10-08-05-00-00-3163053

    PRESS RELEASE
    09 Oct 2025
    Share Share
    AlphaMedix (212Pb-DOTAMTATE) Meets Ph2 Endpoints In GEP-NET Study
    AlphaMedix (212Pb-DOTAMTATE) Meets Ph2 Endpoints In GEP-NET Study

    08 Oct 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-10-08-05-00-00-3163053

    PRESS RELEASE
    08 Oct 2025
    Share Share